Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill reauthorizes and amends the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for fiscal years 2026–2030, updating program goals and activities to emphasize follow-up services, patient navigation, evidence‑based screening strategies, and equity. It authorizes $235,000,000 for each fiscal year 2026–2030, revises reporting cadence and content, removes certain statutory subsections, and requires a Government Accountability Office report by September 30, 2027 on eligibility, trends, and barriers to accessing services.
Disagreement over federal spending levels and new $235M annual authorization
Relative to its intended legislative type, this bill reauthorizes and modifies an existing federal health program by amending the Public Health Service Act, specifying program purposes, changing reporting cadence, authorizing multi-year funding, and mandating a GAO study; it provides clear statutory authority and funding but limited operational and safeguard detail.
This bill reauthorizes and amends the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for fiscal years 2026–2030, updating program goals and activities to emphasize follow-up services, patient navigation, evidence‑based screening strategies, and equity.
It authorizes $235,000,000 for each fiscal year 2026–2030, revises reporting cadence and content, removes certain statutory subsections, and requires a Government Accountability Office report by September 30, 2027 on eligibility, trends, and barriers to accessing services.
The bill explicitly adds language to reduce disparities, improve equitable access, and facilitate implementation of proven screening strategies.
Narrow, non-ideological reauthorization with modest funding and GAO oversight raises probability, but final passage depends on appropriations and legislative calendar.
Relative to its intended legislative type, this bill reauthorizes and modifies an existing federal health program by amending the Public Health Service Act, specifying program purposes, changing reporting cadence, authorizing multi-year funding, and mandating a GAO study; it provides clear statutory authority and funding but limited operational and safeguard detail.
Disagreement over federal spending levels and new $235M annual authorization
These are examples from the analysis, not a ranked list of the most-affected groups.
Disagreement over federal spending levels and new $235M annual authorization
Generally strongly supportive.
The bill expands and funds an established federal program that serves low‑income, uninsured, and underinsured women, adds patient navigation and equity goals, and directs a GAO study to assess access barriers.
Progressives will likely push for even broader funding and stronger links to treatment access, but will view this as a valuable federal public health investment.
Generally supportive but pragmatic.
The bill continues an established federal public health program, codifies evidence‑based strategies and equity aims, and sets a clear funding authorization and GAO oversight.
Moderates will welcome accountability but want clear performance metrics and fiscal clarity on appropriations versus authorizations.
Cautious to somewhat opposed.
While supportive of early detection in principle, mainstream conservatives will question increased federal authorization levels, potential federal overreach into healthcare delivery, and duplication with state programs.
They may accept the bill if spending is constrained, state flexibility preserved, and clear accountability provided.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, non-ideological reauthorization with modest funding and GAO oversight raises probability, but final passage depends on appropriations and legislative calendar.
The bill has not accumulated any surfaced votes yet.
Disagreement over federal spending levels and new $235M annual authorization
Narrow, non-ideological reauthorization with modest funding and GAO oversight raises probability, but final passage depends on appropriatio…
Relative to its intended legislative type, this bill reauthorizes and modifies an existing federal health program by amending the Public Health Service Act, specifying program purposes, changing reporting cadence, autho…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.